The finding comes days before an FDA advisory committee meets to consider whether seven widely used peptides BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon should become eligible for compounding
BPC-157 actively reduces inflammation throughout the body, making it an excellent treatment for conditions like tendonitis, arthritis, and overuse injuries
Others wont, they simply may not know that diagnosing B12 deficiency for the person is key to being able to access B12 from their GP as there is usually a lifelong need and having regular B12 injections from a private clinic would may not be financially sustainable
The molecule was first identified and studied by the Sikiric research group in Croatia starting in the early 1990s, and the bulk of the preclinical evidence base comes from more than three decades of rat and rodent studies showing consistent tissue-repair, anti-inflammatory, and gastroprotective effects